Get to know our clinical trials

Clinical trial of VRd followed by ciltacabtagene autoleucel vs. VRd followed by Rd in patients with multiple myeloma

THE AIM OF THIS STUDY IS TO DETERMINE WHETHER TREATMENT WITH VRD FOLLOWED BY CILTA-CEL IS SAFE AND USEFUL FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA COMPARED TO TREATMENT WITH VRD FOLLOWED BY RD.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • STUDY TO COMPARE TREATMENT WITH VRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VS. TREATMENT WITH VRD FOLLOWED BY RD IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA FOR WHOM HEMATOPOIETIC STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL TREATMENT.
  • Code EudraCT: 2021-001242-35
  • Protocol number: 68284528MMY3004
  • Promoter: JANSSEN
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.